ReviewJournal of clinical and translational hepatology2020
Pathophysiology and Prevention of Paracentesis-induced Circulatory Dysfunction: A Concise Review.
Review in Journal of clinical and translational hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Midodrine Versus Albumin During Large-volume Paracentesis and Its Effect on Paracentesis Induced Circulatory Disturbance in Patients With Acute on Chronic Liver Failure - A Randomized Controlled Trial
Low-Dose Albumin Infusion for the Prevention of Paracentesis Induced Circulatory Dysfunction (PICD), After Large Volume Paracentesis in Decompensated Cirrhosis of Liver.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Low-Dose vs. Standard Care Iv Human Albumin During Large-Volume Paracentesis in Patients With Liver Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin.Hepatology international · 2025Trial
- A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper.Hepatology international · 2026Article
- Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial-Commentary.Cardiovascular and interventional radiology · 2026Article
- Refractory Ascites and the Alfapump.Gastro hep advances · 2026Review
- Human albumin infusion for reducing hyponatremia and circulatory dysfunction in liver cirrhosis: A meta-analysis update.World journal of hepatology · 2025Article
- Understanding acute kidney injury in cirrhosis: Current perspective.World journal of hepatology · 2025Review
- Ascites in patients with end-stage renal disease: Challenges and solutions from diagnosis to management.Hepatology communications · 2025Review
- Observational
- Advances in the management of complications from cirrhosis.Gastroenterology report · 2024Review
- Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management.Kidney research and clinical practice · 2023Article
- Clinical Guideline on Perioperative Management of Patients with Advanced Chronic Liver Disease.Life (Basel, Switzerland) · 2023Review
- Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- The challenges of ascites management: An Indian perspective.Clinical liver disease · 2022Review
- Practice guidance for the use of terlipressin for liver cirrhosis-related complications.Therapeutic advances in gastroenterology · 2022Article
- Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document.Trauma surgery & acute care open · 2022Article
- The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes.Hepatology international · 2021Article
- Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.Journal of clinical and experimental hepatologyReview
- Overview of Complications in Cirrhosis.Journal of clinical and experimental hepatologyReview
- Management of Portal Hypertension.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Annually, 10% of cirrhotic patients with ascites develop refractory ascites for which large-volume paracentesis (LVP) is a frequently used therapeutic procedure. LVP, although a safe method, is associated with circulatory dysfunction in a significant percentage of patients, which is termed paracentesis-induced circulatory dysfunction (PICD). PICD results in faster reaccumulation of ascites, hyponatremia, renal impairment, and shorter survival. PICD is diagnosed through laboratory results, with increases of >50% of baseline plasma renin activity to a value ≥4 ng/mL/h on the fifth to sixth day after paracentesis. In this review, we discuss the pathophysiology and prevention of PICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.